Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STEM -- StemCells, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: HandsOn who wrote (287)	7/27/1999 8:39:00 PM
From: Mike McFarland	Read Replies (3) \| Respond to of 805

Up...up and awaaay, goes my beautiful balloon. Well, maybe not that exciting yet...but gosh, three times average volume. Lessee, 5k shares times 1/4 so far...that's some nice change I'd rather have in my pocket. I want to take this chance to really take back what I said about the tape not being worth listening to. These biotech investor forums are just terrific...and McCamant fills a void, there just are no biotech analysts getting air time, so he is great. I don't know about his track record, and I don't care, he gets these names out in front of folks, it's up to investors to make up their own mind. And it was nice that biospace got Silverman to talk as well...yeah, I really do take that comment back--great stuff, and kudos to Biospace and Vcall as well. informedinvestors.com

To: HandsOn who wrote (287)	7/30/1999 9:20:00 AM
From: Jon Koplik	Read Replies (1) \| Respond to of 805

Just for the record -- text of 7/23/99 news on Dr. Kennedy addition to CTII Board of Directors. Donald Kennedy Joins Board At CytoTherapeutics; Former FDA Commissioner and President Emeritus of Stanford University Business Wire - July 23, 1999 08:13 LINCOLN, R.I.--(BUSINESS WIRE)--July 23, 1999--CytoTherapeutics, Inc. (Nasdaq:CTII) today announced the election of Donald Kennedy, Ph.D., to its Board of Directors. Since 1960, Dr. Kennedy has held a number of academic research, advisory and public policy positions related to health and the environment. Dr. Kennedy currently co-directs the Center for Environmental Science and Policy in the Institute for International Studies at Stanford University in Palo Alto, California. "Dr. Kennedy's considerable expertise in the development of regulatory and public health policies -- combined with his extensive research experience in the field of neurobiology - should immediately impact ongoing development of our proprietary neural stem cell technology," stated Richard M. Rose, M.D., President and Chief Executive Officer. "We are indeed fortunate to draw on Dr. Kennedy's experience to assist us in developing our programs for the Company's human stem cell technologies," added John J. Schwartz, Ph.D., Chairman of the Board. "I am excited to have an opportunity to help advance this exciting technology toward human therapeutic reality," commented Dr. Kennedy. "Stem cell therapy, if successfully developed, could enable the replacement or repair of human tissues and organs. As such, it could prove to be the most significant advancement in medicine to date -- potentially eliminating or reducing the human and monetary costs associated with a number of life-threatening conditions." From 1965 to 1972, Dr. Kennedy served as Chairman of the Department of Biology at Stanford University. In 1973, he helped create and subsequently served as Chairman of an interdisciplinary Program in Human Biology. In 1977, Dr. Kennedy took a leave of absence from Stanford to serve as Commissioner of the United States Food and Drug Administration where he participated in various improvements in the new drug-approval process. Upon his return to Stanford, he was appointed President of Stanford, a position he held for 12 years. Dr. Kennedy received his bachelor and doctorate degrees from Harvard University in Cambridge, Massachusetts. He is a member of the National Academy of Sciences and co-chairs a new Academy program on science and the law. With the election of Dr. Kennedy, CytoTherapeutics' Board now includes seven members. Other CytoTherapeutics' Directors are: --John J. Schwartz, Ph.D., Chairman of the Board of CytoTherapeutics and President of Quantum Strategies Management Company; --Richard M. Rose, M.D., President and Chief Executive Officer of CytoTherapeutics, Inc.; --Moses B. Goddard, M.D., Vice President of CytoTherapeutics, Inc.; --Mark J. Levin, Chief Executive Officer, Millenium Pharmaceuticals, Inc.; --Richard J. Ramsden, a private investor; and --Irving L. Weissman, M.D., Professor of Cancer Biology and Professor, Department of Pathology and Developmental Biology at Stanford University. Copyright © 1999, Hoover's, Inc.